AbbVie Shares Surge 2.37% with $32.68 Billion Trading Volume Ranking 30th as Rinvoq Secures Expanded European Approval

AbbVie (ABBV) shares rose 2.37% on April 9, 2025, with a trading volume of $32.68 billion, ranking 30th in the day's market activity.

AbbVie has secured expanded European approval for its flagship autoimmune drug, Rinvoq, for treating adults with giant cell arteritis. This approval marks the eighth indication for Rinvoq in the European Union, positioning it as the first and only oral advanced therapy available for this inflammatory condition, which can cause symptoms such as headaches, jaw pain, and vision changes, including sudden and permanent vision loss.

The European Commission's approval is a significant milestone for AbbVie, as it broadens the therapeutic applications of Rinvoq. The company had previously projected that Rinvoq's revenue would exceed $11 billion by 2027, and this new indication is expected to further bolster its market position and financial performance.